EFFECTS OF LACTIC ACID BACTERIA PROBIOTIC ON URINARE OXALATE EXCRETION AND PREVENTION OF RECURRENT PYELONEPHRITIS
Abstract
The present study was performed to evaluate the ability of Lactobacillus probiotics to reduce the urinary oxalate excretion level and prevent recurrent pyelonephritis.
Methods. The open, 6 months randomized controlled trial was followed up. 80 women with recurrent pyelonephritis, caused by E. coli or S. faecalis, were randomly allocated into 2 groups. The 1st Group (n = 40) took Symbiform® which contained acidophilic and plantar Lactobacilli, Lactococci (lactis and cremoris), Bifidobacteria (adolescentis and bifidum) and thermophilic non–pathogenic Streptococcus. The 2nd one (n = 40) received oxalate–soluble herbal remedy Uronefron® containing 188 mg of city extract from 9 plants. Probiotic was prescribed in a dose of 1 sachet 2 times a day during the first 5 days, followed by a dose reduction of 1 sachet per day for a month. Uronefron® was prescribed in a dose of 3 pills a day for a month.
Results. 1 month after the end of the treatment, microbiological studies of the colon microflora demonstrated the increasing level of Lactobacillus spp. colonization more than 7 million CPU/1 g of faeces: 35/40 (87.5 %) in the patients of the 1st Group vs 6/40 (15 %) in the women of the comparison Group f/f = 41.5; p < 0.0001).
The levels of daily urinary oxalate excretion were significantly decreased in both groups: the patients of Probiotic Group: 117.6 ± 11.7 vs 71.9 ± 10.07mg/d after the treatment (p < 0.0001) and 122.02 ± 17 vs 84.8 ± 9.8 mg/d (p < 0.0001) in the women of the 2nd Group, respectively.
In the 6 months preceding randomization, at least 1 recurrence of pyelonephritis occurred in 2/40 (5 %) women of the Probiotic Group and 9/40 (22.5 %) in the patients of Group II (//= 5,1; p = 0,02).
Conclusions. The use of lactobacillus probiotics in non–stone fanners women with recurrent pyelonephritis increases the quantitative content of Lactobacillus spp. in the gut, reduces daily urinary oxalate excretion and the number of pyelonephritis recurrences.
Downloads
References
Гіпероксалурія та колонізаційна резистентність кишківника у хворих на пієлонефрит з рецидивуючим перебігом / М. Колесник, Н. Степанова, Н. Сташевська, В. Дріянська // Журнал Національної академії медичних наук України. – 2016. – Т. 22, № 1. – С. 62–69.
Литвинова Е. В. Анализ эффективности и фармакоэкономические аспекты применения отечественных фитопрепаратов в профилактике и лечении мочекаменной болезни / Литвинова Е. В. / – Український біофармацевтичний журнал. – 2014. – № 4. – С. 27–32.
Реброва О. Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA / О. Ю. Реброва. – М.: Медиасфера, 2003. – 312 с.
Ризик зниження Lactobacillus spp. у складі мікробіоти кишківника хворих на інфекцію сечової системи, асоційований з прийомом антибактеріальних лікарських засобів / Н. Степанова, Н. Сташевська, Л. Лебідь, С. Савченко, М. Колесник // Український Журнал Нефрології та Діалізу. – 2017. – № 2 (54). – С. 23–26.
Топчий И. И., Щербань Т. Д., Семеновых П. С. Терапевтические эффекты фитопрепарата Уронефрон у больных хроническим пиелонефритом в сочетании с мочекаменной болезнью. - Медицинские аспекты здоровья мужчины. – 2012. – № 1 (3). – С. 35 –39.
Al–Wahsh I. Acute probiotic ingestion reduces gastrointestinal oxalate absorption in healthy subjects / Al–Wahsh I., Wu Y., Liebman M. // Urol. Res. – 2012. – V. – 40 (3). – Р. 191–196.
Asplin J. R. The management of patients with enteric hyperoxaluria / Asplin J. R. / Urolithiasis. – 2016. – V. – 44 (1). – P.33–43.
Di Cerbo A. Mechanisms and therapeutic effectiveness of lactobacilli / Di Cerbo A., Palmieri B., Aponte M., [et al.] // Journal of Clinical Pathology - 2016. –V. 69 (3). – P. 187–203.
Guidelines on Urological Infections // M. Grabe (Chairman), M. C. Bishop, T. E. Bjerklund–Johansen [et al.] // European Association of Urology. – 2017.
Jiang J. Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion / J. Jiang, J. Knight, L. H. Easter, R. Neiberg [et al.] // J Urol. – 2011. – Vol. 186 (1). – Р. 135–139.
John C. Lieske. Probiotics for prevention of urinary stones. / John C. Lieske // Annals of Translational Medicine. – 2017. – V. – 5(2). – Р. 29.
Kamada N. Control of Pathogens and Pathobionts by the Gut Microbiota / Kamada N., Chen G. Y., Inohara N., et al. – 2013. – Nat Immunol. – V. 14 (7). – Р. 685–690.
Kaufman David W. Oxalobacter formigenes May Reduce the Risk of Calcium Oxalate Kidney Stones / David W. Kaufman, Judith P. Kelly, Gary C. Curhan, Theresa E. Anderson [et al.] // J Am Soc Nephrol. – 2008. – Vol. 19 (6). – Р. 1197–1203.
Mogna L. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? / Mogna L., Pane M., Nicola S., Raiteri E. // J Clin Gastroenterol. – 2014. – V. 48, Suppl 1. – P. 91–95.
Mohsin R. Recurrent urinary tract infections in females / Mohsin R., Mutahir K. S. // J. Pak. Med. Assoc. – 2010. – V. – №. 1. – Р. 55–59.
Nazzal L. Enteric hyperoxaluria: an important cause of end–stage kidney disease / Nazzal L., Puri S., Goldfarb D. // Nephrol. Dial. Transplant. – 2016. V. – 31 (3). – P. 375–382.
Nephropathy in dietary hyperoxaluria: A potentially preventable acute or chronic kidney disease / Glew R. H., Sun Y., Horowitz B. L., et al. // World Journal of Nephrology. – 2014. – V. 3 (4). – P. 122–142.
Panda S. Short–term effect of antibiotics on human gut microbiota (Electronic resource) / Panda S., Elkhader I., Casellas F., Lpez Vivancos J., [et al.] // PLoS One. – 2014. – V. 9 (4). – Mode of access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991704
Stepanova N. Intestinal colonization resistance is associated with hyperoxaluria in the patients with recurrent pyelonephritis / N. Stepanova, M. Kolesnyk, N. Stashevska, V. Driyanska // European Urology Supplements. – 2017. – Vol. 16. – Issue 3. – Р. 402–403.
The antibiotic prophylaxis affect on the colon Oxalobacter formigenes colonization in patients with recurrent pyelonephritis and hyperoxaluria (pilot study) / N. Stepanova, G. Tolstanova, N. Stashevska, N. Dzyubenko, T. Sergiychuk, I. Akulenko // Nephrol Dial Transplant. – 2017. – V. – 32 (suppl 3). – P. iii432–iii433.
